|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03759 PHARMARON
Nominal 
15.400 +0.180 (+1.183%) Ranking Overview
Ranking based on 8 research report(s)
Average Ranking 2.13
|
Strong Buy (1)
0
|
Buy (2)
7
|
Hold (3)
1
|
Sell (4)
0
|
Strong Sell (5)
0
|
Previous Financial Performance
| Financial Year | 12/2023 | EPS | 90.33 RMB (cts) | |
| Net Profit | 1,601.10 RMB (MIL) | DPS | 20.00 RMB (cts) |
Consolidation Estimation
| Financial Year | Profit / (Loss) (RMB (MIL)) |
EPS/ ((LPS)(RMB (cts)) |
DPS (RMB (cts)) |
Net Asset Value per Share (RMB) |
Highest (RMB (MIL)) |
Lowest (RMB (MIL)) |
| 2024 | 1,862.00 | 105.00 | 23.00 | -- | 2,049.00 | 1,742.30 |
| 2025 | 1,879.00 | 105.50 | 23.30 | -- | 2,178.00 | 1,530.00 |
| 2026 | 2,223.00 | 124.00 | 25.45 | -- | 2,504.00 | 1,722.00 |
Profit Estimation
| Profit Estimation | Profit / (Loss) (RMB (MIL)) |
EPS*/ (LPS) (RMB (cts)) |
DPS * (RMB (cts)) |
Broker | Ranking | Target Price* (HKD) |
Update Date | |
| 2024 | 1,742.30 | 98.00 | 24.00 | GOLDMAN SACHS | Buy | 20.00 | 28/08/2024 | |
| 2024 | 1,816.00 | 102.00 | 20.00 | CLSA | OutPerform | 19.10 | 30/10/2024 | |
| 2024 | 1,918.00 | 107.00 | -- | MORGAN STANLEY | Overweight | 15.70 | 25/09/2024 | |
| 2024 | 1,875.00 | 106.00 | -- | NOMURA | Buy | 14.31 | 27/08/2024 | |
| 2024 | 1,955.00 | 109.00 | 27.00 | UBS | Buy | 13.30 | 02/09/2024 | |
| 2024 | 2,049.00 | 116.00 | 27.00 | CCBI | OutPerform | 12.50 | 22/07/2024 | |
| 2024 | 1,795.00 | 100.00 | 23.00 | CICC | OutPerform | 12.30 | 28/08/2024 | |
| 2024 | 1,849.00 | 104.00 | 18.50 | BANK OF AMERICA | Neutral | 9.00 | 28/08/2024 | |
| 2025 | 2,017.80 | 114.00 | 21.00 | GOLDMAN SACHS | -- | -- | 28/08/2024 | |
| 2025 | 1,530.00 | 86.00 | 20.00 | CLSA | -- | -- | 30/10/2024 | |
| 2025 | 1,761.00 | 99.00 | -- | MORGAN STANLEY | -- | -- | 25/09/2024 | |
| 2025 | 1,862.00 | 105.00 | -- | NOMURA | -- | -- | 27/08/2024 | |
| 2025 | 1,896.00 | 106.00 | 27.00 | UBS | -- | -- | 02/09/2024 | |
| 2025 | 2,082.00 | 117.00 | 25.00 | CCBI | -- | -- | 22/07/2024 | |
| 2025 | 2,178.00 | 122.00 | 27.00 | CICC | -- | -- | 28/08/2024 | |
| 2025 | 1,794.00 | 100.00 | 23.30 | BANK OF AMERICA | -- | -- | 28/08/2024 | |
| 2026 | 2,333.60 | 132.00 | 24.00 | GOLDMAN SACHS | -- | -- | 28/08/2024 | |
| 2026 | 1,722.00 | 96.00 | 20.00 | CLSA | -- | -- | 30/10/2024 | |
| 2026 | 2,391.00 | 134.00 | -- | MORGAN STANLEY | -- | -- | 25/09/2024 | |
| 2026 | 2,183.00 | 123.00 | -- | NOMURA | -- | -- | 27/08/2024 | |
| 2026 | 2,223.00 | 124.00 | 31.00 | UBS | -- | -- | 02/09/2024 | |
| 2026 | 2,504.00 | 141.00 | 28.00 | CCBI | -- | -- | 22/07/2024 | |
| 2026 | 2,061.00 | 115.00 | 26.90 | BANK OF AMERICA | -- | -- | 28/08/2024 | |
| Remarks: | Average rating ranges from 1 to 5. The lower the figure, the higher the rating and the vice versa. |
| *EPS, DPS and Estimated Price would be adjusted upon Consolidation, Split and Bonus Issue | |
| Real time quote last updated: 04/11/2024 17:59 | |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,113,403 |
| %Change | 41.638% |
| EPS / (LPS) | RMB 0.628 |
| NBV Per Share (¥) | RMB 7.280 |